A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

June 8, 2026

Study Completion Date

June 8, 2026

Conditions
Radiation-induced Xerostomia
Interventions
DRUG

Spermidine

As a member of the polyamine family, spermidine is a trivalent cationic compound found in eukaryotic cells. It interacts with polyanions such as nucleic acids, proteins, and ATP through electrostatic binding, thereby maintaining genomic DNA stability, regulating gene transcription and translation, and modulating autophagy, apoptosis, oxidative stress, angiogenesis, and intercellular communication. Spermidine is indispensable for cell division and proliferation.

DRUG

Spermidine simulants

Patients in control group were treated with Spermidine simulants, and its use method and use time are the same as intervention group.

Trial Locations (1)

610000

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER

NCT07035626 - A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma) | Biotech Hunter | Biotech Hunter